prikaz prve stranice dokumenta A multi-centre longitudinal study analysing multiple sclerosis disease-modifying therapy prescribing patterns during the COVID-19 pandemic
  Download
PDF 600.76 KB
Scientific paper - Original scientific paper
A multi-centre longitudinal study analysing multiple sclerosis disease-modifying therapy prescribing patterns during the COVID-19 pandemic
Journal of Neurology, 271 (2024), 9; 5813-5824. https://doi.org/10.1007/s00415-024-12518-7
Lal, Anoushka P.; Foong, Yi Chao; Sanfilippo, Paul G.; Spelman, Tim; Rath, Louise; Levitz, David; Fabis-Pedrini, Marzena; Foschi, Matteo; Habek, Mario; Kalincik, Tomas; Roos, Izanne; Lechner-Scott, Jeannette; John, Nevin; Soysal, Aysun; D’Amico, Emanuele; Gouider, Riadh; Mrabet, Saloua; Gross-Paju, Katrin; Cárdenas-Robledo, Simón; Moghadasi, Abdorreza Naser; Sa, Maria Jose; Gray, Orla; Oh, Jiwon; Reddel, Stephen; Ramanathan, Sudarshini; Al-Harbi, Talal; Altintas, Ayse; Hardy, Todd A.; Ozakbas, Serkan; Alroughani, Raed; Kermode, Allan G.; Surcinelli, Andrea; Laureys, Guy; Eichau, Sara; Prat, Alexandre; Girard, Marc; Duquette, Pierre; Hodgkinson, Suzanne; Ramo-Tello, Cristina; Maimone, Davide; McCombe, Pamela; Spitaleri, Daniele; Sanchez-Menoyo, Jose Luis; Yetkin, Mehmet Fatih; Baghbanian, Seyed Mohammad; Karabudak, Rana; Al-Asmi, Abdullah; Jakob, Gregor Brecl; Khoury, Samia J.; Etemadifar, Masoud; van Pesch, Vincent; Buzzard, Katherine; Taylor, Bruce; Butzkueven, Helmut; Van der Walt, Anneke More authors...

Cite this document

Lal, A. P., Foong, Y. C., Sanfilippo, P. G., Spelman, T., Rath, L., Levitz, D. ... Van der Walt, A. (2024). A multi-centre longitudinal study analysing multiple sclerosis disease-modifying therapy prescribing patterns during the COVID-19 pandemic. Journal of Neurology, 271. (9), 5813-5824. doi: 10.1007/s00415-024-12518-7

Lal, Anoushka P., et al. "A multi-centre longitudinal study analysing multiple sclerosis disease-modifying therapy prescribing patterns during the COVID-19 pandemic." Journal of Neurology, vol. 271, no. 9, 2024, pp. 5813-5824. https://doi.org/10.1007/s00415-024-12518-7

Lal, Anoushka P., Yi Chao Foong, Paul G. Sanfilippo, Tim Spelman, Louise Rath, David Levitz, Marzena Fabis Pedrini, et al. "A multi-centre longitudinal study analysing multiple sclerosis disease-modifying therapy prescribing patterns during the COVID-19 pandemic." Journal of Neurology 271, no. 9 (2024): 5813-5824. https://doi.org/10.1007/s00415-024-12518-7

Lal, A. P., et al. (2024) 'A multi-centre longitudinal study analysing multiple sclerosis disease-modifying therapy prescribing patterns during the COVID-19 pandemic', Journal of Neurology, 271(9), pp. 5813-5824. doi: 10.1007/s00415-024-12518-7

Lal AP, Foong YC, Sanfilippo PG, Spelman T, Rath L, Levitz D, and sur.. A multi-centre longitudinal study analysing multiple sclerosis disease-modifying therapy prescribing patterns during the COVID-19 pandemic. Journal of Neurology [Internet]. 2024 June 27 [cited 2024 December 19];271(9):5813-5824. doi: 10.1007/s00415-024-12518-7

A. P. Lal, et al., "A multi-centre longitudinal study analysing multiple sclerosis disease-modifying therapy prescribing patterns during the COVID-19 pandemic", Journal of Neurology, vol. 271, no. 9, pp. 5813-5824, June 2024. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:528442. [Accessed: 19 December 2024]

Please login to the repository to save this object to your list.
Metadata
Title (english)A multi-centre longitudinal study analysing multiple sclerosis disease-modifying therapy prescribing patterns during the COVID-19 pandemic
AuthorAnoushka P. Lal
AuthorYi Chao Foong
AuthorPaul G. Sanfilippo
AuthorTim Spelman
AuthorLouise Rath
AuthorDavid Levitz
AuthorMarzena Fabis-Pedrini
AuthorMatteo Foschi
AuthorMario Habek
AuthorTomas Kalincik
AuthorIzanne Roos
AuthorJeannette Lechner-Scott
AuthorNevin John
AuthorAysun Soysal
AuthorEmanuele D’Amico
AuthorRiadh Gouider
AuthorSaloua Mrabet
AuthorKatrin Gross-Paju
AuthorSimón Cárdenas-Robledo
AuthorAbdorreza Naser Moghadasi
AuthorMaria Jose Sa
AuthorOrla Gray
AuthorJiwon Oh
AuthorStephen Reddel
AuthorSudarshini Ramanathan
AuthorTalal Al-Harbi
AuthorAyse Altintas
AuthorTodd A. Hardy
AuthorSerkan Ozakbas
AuthorRaed Alroughani
AuthorAllan G. Kermode
AuthorAndrea Surcinelli
AuthorGuy Laureys
AuthorSara Eichau
AuthorAlexandre Prat
AuthorMarc Girard
AuthorPierre Duquette
AuthorSuzanne Hodgkinson
AuthorCristina Ramo-Tello
AuthorDavide Maimone
AuthorPamela McCombe
AuthorDaniele Spitaleri
AuthorJose Luis Sanchez-Menoyo
AuthorMehmet Fatih Yetkin
AuthorSeyed Mohammad Baghbanian
AuthorRana Karabudak
AuthorAbdullah Al-Asmi
AuthorGregor Brecl Jakob
AuthorSamia J. Khoury
AuthorMasoud Etemadifar
AuthorVincent van Pesch
AuthorKatherine Buzzard
AuthorBruce Taylor
AuthorHelmut Butzkueven
AuthorAnneke Van der Walt
Author's institutionUniversity of Zagreb
School of Medicine
(Department of Neurology)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Neurology
Abstract (english)
Background: The COVID-19 pandemic raised concern amongst clinicians that disease-modifying therapies (DMT), particularly anti-CD20 monoclonal antibodies (mAb) and fingolimod, could worsen COVID-19 in people with multiple sclerosis (pwMS). This study aimed to examine DMT prescribing trends pre- and post-pandemic onset. Methods: A multi-centre longitudinal study with 8,771 participants from MSBase was conducted. Two time periods were defined: pre-pandemic (March 11 2018-March 10 2020) and post-pandemic onset (March 11 2020-11 March 2022). The association between time and prescribing trends was analysed using multivariable mixed-effects logistic regression. DMT initiation refers to first initiation of any DMT, whilst DMT switches indicate changing regimen within 6 months of last use. Results: Post-pandemic onset, there was a significant increase in DMT initiation/switching to natalizumab and cladribine [(Natalizumab-initiation: OR 1.72, 95% CI 1.39-2.13; switching: OR 1.66, 95% CI 1.40-1.98), (Cladribine-initiation: OR 1.43, 95% CI 1.09-1.87; switching: OR 1.67, 95% CI 1.41-1.98)]. Anti-CD20mAb initiation/switching decreased in the year of the pandemic, but recovered in the second year, such that overall odds increased slightly post-pandemic (initiation: OR 1.26, 95% CI 1.06-1.49; Switching: OR 1.15, 95% CI 1.02-1.29. Initiation/switching of fingolimod, interferon-beta, and alemtuzumab significantly decreased [(Fingolimod-initiation: OR 0.55, 95% CI 0.41-0.73; switching: OR 0.49, 95% CI 0.41-0.58), (Interferon-gamma-initiation: OR 0.48, 95% CI 0.41-0.57; switching: OR 0.78, 95% CI 0.62-0.99), (Alemtuzumab-initiation: OR 0.27, 95% CI 0.15-0.48; switching: OR 0.27, 95% CI 0.17-0.44)]. Conclusions: Post-pandemic onset, clinicians preferentially prescribed natalizumab and cladribine over anti-CD20 mAbs and fingolimod, likely to preserve efficacy but reduce perceived immunosuppressive risks. This could have implications for disease progression in pwMS. Our findings highlight the significance of equitable DMT access globally, and the importance of evidence-based decision-making in global health challenges.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleJournal of Neurology
Numberingvol. 271, no. 9, pp. 5813-5824
p-ISSN0340-5354
e-ISSN1432-1459
DOIhttps://doi.org/10.1007/s00415-024-12518-7
URN:NBNurn:nbn:hr:105:528442
Publication2024-06-27
Document URLhttps://link.springer.com/10.1007/s00415-024-12518-7
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution 4.0 International (CC BY 4.0) icon
Created on2024-12-17 10:36:27